GlassScriptPhysician profile
Aaron T Henderson
NPI 1316231129
$9,416.58
in general payments reported to CMS, 2019-2025
66 companies · $2,406 in 2025
The $2,406 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.41 · 2020: $20.04 · 2022: $911 · 2023: $2,917 · 2024: $3,137 · 2025: $2,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,425 · Education: $34.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,425.41 |
| Education | $34.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $816.75 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $799.31 | 2022-2025 | Kisqali, Piqray |
| Regeneron Healthcare Solutions, INC. | $605.22 | 2022-2025 | Libtayo |
| Janssen Biotech, INC. | $539.08 | 2022-2025 | Carvykti, Darzalex, Imbruvica |
| Merck Sharp & Dohme LLC | $423.14 | 2022-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $416.91 | 2022-2025 | Opdivo, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $331.69 | 2019-2025 | Lynparza, Calquence, Enhertu |
| Lilly USA, LLC | $319.19 | 2022-2025 | Jaypirca, Retevmo, Verzenio |
| Amgen INC. | $310.15 | 2022-2025 | Xgeva, Nplate, Vectibix |
| Genzyme Corporation | $276.24 | 2022-2025 | |
| Astellas Pharma US INC | $269.63 | 2020-2025 | Padcev, Xtandi, Xospata |
| Daiichi Sankyo INC. | $252.90 | 2023-2025 | Enhertu, Datroway |
| Pfizer INC. | $242.41 | 2022-2025 | |
| Abbvie INC. | $240.95 | 2024-2025 | |
| Stemline Therapeutics INC. | $210.71 | 2023-2025 | Orserdu, Elzonris |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $192.55 | 2023-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $189.90 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Array Biopharma INC | $159.95 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $157.53 | 2022-2025 | Polivy, Tecentriq, Columvi |
| Ipsen Biopharmaceuticals, INC | $140.92 | 2022-2025 | Onivyde, Somatuline Depot |
| Blueprint Medicines Corporation | $134.02 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $130.57 | 2023-2025 | Ninlaro, Vpriv |
| Beone Medicines USA, INC. | $125.74 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $119.47 | 2022-2025 | Monoferric |
| Sumitomo Pharma America, INC. | $117.41 | 2023-2025 | Orgovyx |
| Recordati_rare_diseases_inc. | $115.54 | 2023-2024 | Sylvant |
| Seagen INC. | $114.96 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Deciphera Pharmaceuticals INC. | $114.89 | 2023-2025 | Qinlock, Romvimza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.57 | 2023-2025 | Gilotrif |
| Incyte Corporation | $97.10 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Jazz Pharmaceuticals INC. | $93.40 | 2022-2025 | |
| Pharmaessentia USA Corporation | $89.83 | 2023-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $89.28 | 2023-2025 | Fotivda |
| Emd Serono, INC. | $72.32 | 2022-2025 | |
| Coherus Oncology, INC. | $69.80 | 2024 | |
| Mirati Therapeutics, INC. | $57.20 | 2023-2024 | Krazati |
| Beigene USA, INC. | $56.07 | 2022-2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $53.55 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Eisai INC. | $50.74 | 2024-2025 | |
| Tersera Therapeutics LLC | $50.13 | 2022-2023 | Quzyttir |
| Pharming Healthcare, INC. | $40.59 | 2023 | Ruconest |
| Springworks Therapeutics, INC. | $40.17 | 2024-2025 | Ogsiveo |
| Tempus Ai, INC | $40.09 | 2024-2025 | Xt Cdx |
| Sobi, INC | $39.20 | 2023-2024 | |
| Celltrion USA INC. | $37.60 | 2025 | Vegzelma |
| Spectrum Pharmaceuticals INC. | $36.35 | 2023 | Rolvedon |
| Adaptive Biotechnologies Corporation | $31.92 | 2022-2023 | Clonoseq |
| Gilead Sciences, INC. | $31.33 | 2019-2025 | Trodelvy |
| Taiho Oncology, INC. | $30.78 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $29.73 | 2023 | Tecvayli |
| Puma Biotechnology, INC. | $27.39 | 2023-2024 | |
| Myovant Sciences INC. | $26.73 | 2022 | |
| Genmab U.S., INC. | $24.78 | 2023 | Epkinly |
| Syndax Pharmaceuticals, INC. | $24.38 | 2025 | |
| Adc Therapeutics America, INC. | $19.06 | 2023 | |
| Paratek Pharmaceuticals, INC. | $18.56 | 2023 | Nuzyra |
| Immunogen, INC. | $18.51 | 2023 | Elahere |
| Iovance Biotherapeutics, INC. | $18.20 | 2024 | Amtagvi |
| Karyopharm Therapeutics INC. | $17.09 | 2024 | Xpovio |
| Alexion Pharmaceuticals, INC. | $17.02 | 2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $16.87 | 2023 | |
| Morphosys, US INC. | $16.67 | 2023 | Monjuvi |
| Amneal Pharmaceuticals LLC | $15.53 | 2024 | Avastin |
| Fennec Pharmaceuticals, INC. | $15.14 | 2023 | Pedmark |
| Verity Pharmaceuticals INC. | $14.89 | 2023 | Trelstar |
| Acrotech Biopharma INC. | $14.28 | 2024 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.